Quick Answer
Pasithea Therapeutics Corp. reported Total Assets of $60.24 million for the year ending 2025.
- Pasithea Therapeutics Corp. showed an increase of +275.0% in Total Assets from 2024 to 2025.
- This data is from Pasithea Therapeutics Corp.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $21.04 million | Q1 2022: $51.08 million | Q2 2022: $53.03 million | Q3 2022: $49.61 million | Q1 2023: $42.04 million | Q2 2023: $38.15 million | Q3 2023: $30.66 million | Q1 2024: $22.41 million | Q2 2024: $17.66 million | Q3 2024: $18.64 million | Q1 2025: $14.66 million | Q2 2025: $17.01 million | Q3 2025: $13.63 million.
- Over the full 6 years of available data (2020 to 2025), Pasithea Therapeutics Corp.'s Total Assets has grown by 24,194.5%.
- Historical annual values: Fiscal year 2025: $60.24 million | Fiscal year 2024: $16.06 million | Fiscal year 2023: $26.12 million | Fiscal year 2022: $45.18 million | Fiscal year 2021: $53.32 million | Fiscal year 2020: $248.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: